Molecule
Molecule is a Swiss technology company building decentralized science (DeSci) infrastructure that democratizes research funding and tokenizes intellectual property.
Last updated September 29, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Molecule is a technology company operating at the intersection of biotechnology and blockchain, focused on advancing scientific research through democratized funding and the tokenization of intellectual property (IP). Founded in 2019, the company describes itself as a first mover and market leader in the Decentralized Science (DeSci) ecosystem. Its flagship product, Molecule Labs, brings funding, collaboration, and visible progress into a single shared platform, helping scientific projects move forward with less friction. The platform connects funders seeking early-stage research with thesis-driven biotech labs, allowing them to track capital use, milestones, and progress updates in real time. Researchers gain access to resources, streamlined fundraises, and a collaborative ecosystem to build and scale their work. Molecule's model includes a "Coin-to-Company" pathway, a compliant route from community to cap table. This dual-track structure combines a token track—where communities can buy project tokens, unlock token-gated research data, and participate in on-chain governance—with a company track where token holders may apply to become shareholders. Through locked tokens, the company raises capital, employs teams, holds IP portfolios, and issues equity to investors and service providers under standard U.S. securities exemptions. The company states that equity issued through Coin-to-Company qualifies for significant U.S. tax advantages, including potential capital gains exclusions for qualifying small business stock. Molecule has founded several leading DeSci organizations, including BIO Protocol, VitaDAO, and pump.science. It has received backing from investors such as Northpond Ventures, Pfizer Ventures, Balaji Srinivasan, Yzi Labs, Shine Capital, and Maelstrom. The company is headquartered in Switzerland and operates globally, with a team led by founder and chairman Paul Kohlhaas. Its mission is to make science more transparent, collaborative, and impactful by aligning the incentives of researchers and funders.
History
Molecule was founded in 2019 with the goal of advancing scientific research through democratized funding and the tokenization of intellectual property. Operating at the intersection of biotechnology and blockchain, the company emerged as an early participant in the decentralized science (DeSci) movement, which seeks to improve modern science using blockchain tools. Molecule describes itself as a first mover and market leader in this ecosystem. In its early years, Molecule founded several leading DeSci organizations, including BIO Protocol, VitaDAO, and pump.science. These entities helped establish the company's presence in the space and demonstrated its model of aligning capital and shared infrastructure. The company also attracted backing from notable investors such as Northpond Ventures, Pfizer Ventures, Balaji Srinivasan, Yzi Labs, Shine Capital, and Maelstrom. A key development in Molecule's history was the creation of its flagship product, Molecule Labs, which brings funding, collaboration, and visible progress into one shared platform. The platform allows funders to access early-stage research and track capital use, milestones, and progress updates in real time, while researchers can raise aligned capital and connect with leading experts and patients. Molecule also introduced the "Coin-to-Company" model, a compliant path from community to cap table. This dual-track structure combines a token track—where communities can buy project tokens, unlock token-gated research data, and participate in on-chain governance—with a company track where token holders may apply to become shareholders. Through locked tokens, the company raises capital, employs teams, holds IP portfolios, and issues equity under standard U.S. securities exemptions. The model is designed to provide tax advantages, liability reduction, and institutional compliance. As of the latest available information, Molecule continues to operate globally from its headquarters in Switzerland, led by founder and chairman Paul Kohlhaas and a team of executives with expertise in law, product, commercial strategy, and protocol architecture.
- 2019
Molecule founded, beginning operations in the decentralized science space.
Founded leading DeSci organizations BIO Protocol, VitaDAO, and pump.science.
Launched flagship product Molecule Labs.
Introduced the Coin-to-Company model for compliant community-to-equity pathways.
Products and positioning
First mover and market leader in the Decentralized Science (DeSci) ecosystem, combining aligned capital and shared infrastructure to make science more transparent, collaborative, and impactful.
Molecule Labs
Flagship platform bringing funding, collaboration, and visible progress into one shared platform for scientific projects.
Coin-to-Company
A compliant dual-track model providing a voluntary, legally grounded route for token holders to gain equity ownership in projects.
Recent events
Molecule framework enables biopharma IP transfer to VitaDAO[5]
Reported:
Molecule, working with Nevermined, enabled a biopharma IP-to-NFT transfer to VitaDAO. VitaDAO acquired IP resulting from longevity research at the Danish Scheibye-Knudsen Lab. The source describes this as the first biopharma IPNFT transfer.
MOLECULE launches CopperWELL Sleep Collection exclusively at MattressFirm.com[6]
Reported:
MOLECULE announced the launch of its CopperWELL Mattress Collection, exclusive to MattressFirm.com. The collection includes mattresses and a foam pillow.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/molecule-gmbh · Editorial policy · How profiles are compiled